Drawing based on the label description. No photo yet.
“Each brown mottled, round, flat-faced beveled-edge tablet contains 75 mg ferrous fumarate and is debossed with 'S' on one side and '57' on other side of the tablet”
S 57 pill
Pill with imprint S 57 is brown, round, 6 mm and has been identified as Inert. It is supplied by Rpk Pharmaceuticals, Inc.
Inert
- Imprint
- S 57
- Color
- Brown
- Shape
- Round
- Size
- 6 mm
- Score
- No score line
- Form
- Tablet
- Manufacturer
- Rpk Pharmaceuticals, Inc
- NDC
- 53002-3711, 50102-228, 53002-3711-1, 53002-3711-3, 53002-3711-6, 65862-940, 65862-940-87, 65862-940-88, 65862-940-58, 65862-941, 65862-941-87, 65862-941-58, 65862-941-88, 50102-228-21, 50102-228-23
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
Is this your pill? Check every detail
- One side shows S and the other side shows 57.
- It is brown, round, 6 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
One of the pills in the Tarina Fe 1/20 Eq pack.
This pill has no active ingredient (a placebo or reminder pill).
Ingredients
Inactive: Ferrous Fumarate, Spearmint, Sucralose
Also distributed by
Aurobindo Pharma Limited, Afaxys Pharma, LLC
Other pills with imprint S 57
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
NL 5
Nebivolol 5 mg
Brown, round, 7 mm
Used for severe high blood pressure
-
L22
Levothyroxine Sodium 0.125 mg
Brown, round, 6 mm
Used for goiter and myxedema
-
9 3
Pramipexole Dihydrochloride 0.5 mg
Brown, round, 7 mm
Used for depression and Parkinson's disease
-
G 49
Chlorpromazine Hydrochloride 10 mg
Brown, round, 6 mm
Used for anxiety and schizophrenia
-
JSP 519
Levothyroxine Sodium 125 mcg
Brown, round, 7 mm
Used for goiter and myxedema
-
G77
Oxymorphone Hydrochloride 30 mg
Brown, round, 5 mm
Used for pain
Schedule II

